How big is the GLP-1 market? Exploring its growth potential By
GLP-1 receptor agonists are changing the way chronic conditions like type 2 diabetes are managed, but they have also been approved in the United States to treat obesity, resulting in investors assessing the various outcomes if they become more widely adopted. But how big is the market for these…#glp1 #goldmansachs #fatimacodystanford #glp1s #mit #jonathangruber #novonordiskas #medicare #goldman #biotech
Source: Reuters: Health - Category: Consumer Health News Source Type: news
More News: Biotechnology | Diabetes | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Health | Medicare | Obesity | USA Health